Respiratory syncytial virus prefusion F3 vaccine in lung transplant recipients elicits CD4+ T cell response in all vaccinees
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F25%3A10496696" target="_blank" >RIV/00216208:11110/25:10496696 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/25:10496696 RIV/00064203:_____/25:10496696 RIV/00064165:_____/25:10496696
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=urLR3hnq8h" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=urLR3hnq8h</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ajt.2025.03.025" target="_blank" >10.1016/j.ajt.2025.03.025</a>
Alternative languages
Result language
angličtina
Original language name
Respiratory syncytial virus prefusion F3 vaccine in lung transplant recipients elicits CD4+ T cell response in all vaccinees
Original language description
Respiratory syncytial virus (RSV) causes seasonal acute respiratory illness significantly impacting vulnerable groups, including lung transplant recipients (LTRs), who are at increased risk of hospitalization, acute rejection, and allograft dysfunction. The immunogenicity of the novel RSV Prefusion F3 (RSVPreF3-AS01, Arexvy, GlaxoSmithKline) vaccine in immunocompromised patients remains largely unknown. In this study, we assessed both antibody using and cellular immune responses two months after a single dose of the RSVPreF3-AS01 vaccine in 30 LTRs aged 60 years or older, who were at least six months post-transplant. The antibody response was assessed using enzyme-linked immuno sorbent assay for detection of serum anti RSV-F IgG specific antibodies, and the CD4+ T-cell response was measured by flow cytometry intracellular cytokine secretion assay. Our findings show that all vaccinees exhibited a CD4+ T-cell response two months post-vaccination, while only 40% demonstrated an antibody response. These results suggest that some patients may derive clinical benefit from the vaccine through cellular immunity, even without an antibody response. Furthermore, the vaccine was well tolerated in this vulnerable population, with no major safety concerns observed.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30212 - Surgery
Result continuities
Project
<a href="/en/project/NU22-05-00402" target="_blank" >NU22-05-00402: Specific postvaccination immune response against viral pathogens in immunocompromised patients</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
American Journal of Transplantation
ISSN
1600-6135
e-ISSN
1600-6143
Volume of the periodical
25
Issue of the periodical within the volume
7
Country of publishing house
US - UNITED STATES
Number of pages
9
Pages from-to
1452-1460
UT code for WoS article
001532622900001
EID of the result in the Scopus database
2-s2.0-105003209371